GlassScriptPhysician profile
Wykeisha Highsmith
NPI 1386791051
$1,756.56
in general payments reported to CMS, 2019-2025
23 companies · $878 in 2025
The $878 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $220 · 2024: $659 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,708 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,707.72 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $165.37 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.32 | 2023-2025 | Caplyta |
| Tris Pharma INC | $131.56 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Teva Pharmaceuticals USA, INC. | $126.45 | 2023-2025 | Austedo Xr, Austedo Xr |
| Alkermes, INC. | $118.17 | 2023-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $112.29 | 2023-2025 | Rexulti |
| Lundbeck LLC | $104.37 | 2024 | Rexulti |
| Neurocrine Biosciences, INC. | $97.95 | 2025 | |
| Neos Therapeutics, LP | $93.47 | 2023-2025 | Adzenys Xr-Odt, Exxua |
| Abbvie INC. | $89.47 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $79.53 | 2025 | Spravato, Invega Sustenna |
| Ironshore Pharmaceuticals INC. | $66.09 | 2024 | |
| Axsome Therapeutics, INC. | $63.38 | 2024-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $61.03 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $57.07 | 2023-2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $40.91 | 2024-2025 | Wellbutrin, Aplenzin |
| Idorsia Pharmaceuticals US INC | $37.13 | 2023-2025 | Quviviq, Quviviq |
| Vanda Pharmaceuticals INC. | $32.57 | 2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $29.17 | 2024-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $28.97 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $20.21 | 2023 | Xelstrym |
| Boston Scientific Corporation | $19.92 | 2025 | Rezum Generator |
| Owp Pharmaceuticals, INC. | $19.16 | 2025 | Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wykeisha Highsmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.